Company intelligence / Profile preview
Xuanzhu Biopharmaceutical
Chinaprnewswire.com ↗
- Ownership
- Private
- Employees
- ~400
- Development stage
- Other
01
Overview
Xuanzhu Biopharmaceutical has achieved commercial approval for multiple innovative drugs in China. Notably, bireociclib tablets (Xuanyuening®), a CDK4/6 inhibitor for HR+/HER2– advanced or metastatic breast cancer, were approved in May 2025. Anaprozole sodium enteric-coated tablets became the first fully independently developed proton pump inhibitor approved in China for duodenal ulcer in June 2023. The company’s pipeline includes several late-stage assets targeting oncology and other high-growth therapeutic areas[5][6][7].
- Therapeutic areas
- Infectious DiseasesGastroenterologyMetabolic DisordersOncology
- Modalities
- Small moleculeAntibody-drug conjugateDegradable molecular glueChemical drugBiologicsBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
Request access →03
Partnerships
Innovent Biologics – clinical trial collaboration on combination therapy with sintilimab and novel ADC candidate KM‑501 for advanced solid tumors in China[10]
Beyond the preview
Go deeper on Xuanzhu Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xuanzhu Biopharmaceutical.